ERBB2 and neoplasm: Furthermore, there are retrospective studies showing a benefit of endocrine therapy alone (for HER2+/ER+ tumours) but not chemotherapy with/without trastuzumab, for women with HER2-positive pT1abN0 tumours [19, 20].